RxSight (RXST) Competitors $13.18 -0.52 (-3.80%) Closing price 04:00 PM EasternExtended Trading$13.94 +0.76 (+5.73%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. WRBY, NVCR, LMAT, ENOV, EYE, CNMD, CDRE, TNDM, AORT, and LQDAShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), Enovis (ENOV), National Vision (EYE), CONMED (CNMD), Cadre (CDRE), Tandem Diabetes Care (TNDM), Artivion (AORT), and Liquidia (LQDA). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors Warby Parker NovoCure LeMaitre Vascular Enovis National Vision CONMED Cadre Tandem Diabetes Care Artivion Liquidia RxSight (NASDAQ:RXST) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Is RXST or WRBY more profitable? Warby Parker has a net margin of -1.79% compared to RxSight's net margin of -17.90%. Warby Parker's return on equity of -2.48% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-17.90% -9.54% -8.51% Warby Parker -1.79%-2.48%-1.29% Which has stronger earnings and valuation, RXST or WRBY? Warby Parker has higher revenue and earnings than RxSight. Warby Parker is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$139.93M3.83-$27.45M-$0.67-19.67Warby Parker$771.32M2.95-$20.39M-$0.12-181.42 Which has more risk & volatility, RXST or WRBY? RxSight has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Warby Parker has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Do analysts prefer RXST or WRBY? RxSight currently has a consensus price target of $37.90, indicating a potential upside of 187.56%. Warby Parker has a consensus price target of $22.88, indicating a potential upside of 5.08%. Given RxSight's higher probable upside, equities research analysts clearly believe RxSight is more favorable than Warby Parker.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 2 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.30Warby Parker 0 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.61 Does the media favor RXST or WRBY? In the previous week, Warby Parker had 3 more articles in the media than RxSight. MarketBeat recorded 5 mentions for Warby Parker and 2 mentions for RxSight. RxSight's average media sentiment score of 1.45 beat Warby Parker's score of 0.73 indicating that RxSight is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Warby Parker 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of RXST or WRBY? 78.8% of RxSight shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 18.2% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryWarby Parker beats RxSight on 12 of the 16 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$556.73M$6.69B$5.42B$8.73BDividend YieldN/A1.04%5.37%4.21%P/E Ratio-19.6726.8825.0319.34Price / Sales3.8384.66404.73112.13Price / CashN/A20.9135.9456.46Price / Book1.894.687.985.50Net Income-$27.45M$173.18M$3.14B$248.18M7 Day Performance-4.97%1.45%0.89%0.76%1 Month Performance-15.94%-0.61%5.18%4.44%1 Year Performance-76.54%22.61%37.53%16.92% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight3.1562 of 5 stars$13.18-3.8%$37.90+187.6%-75.4%$556.73M$139.93M-19.67220Positive NewsWRBYWarby Parker1.6125 of 5 stars$21.75-1.4%$22.88+5.2%+39.6%$2.27B$795.09M-80.553,030NVCRNovoCure4.2862 of 5 stars$17.91+2.1%$32.83+83.3%-9.2%$2.00B$621.71M-12.791,320Positive NewsLMATLeMaitre Vascular2.8343 of 5 stars$82.10+1.2%$97.83+19.2%+5.7%$1.85B$226.26M44.86490Positive NewsENOVEnovis2.7233 of 5 stars$32.25+1.1%$58.00+79.8%-29.0%$1.84B$2.15B-14.736,800EYENational Vision3.2038 of 5 stars$22.35+3.9%$17.75-20.6%+78.7%$1.77B$1.85B-111.7414,000CNMDCONMED4.3549 of 5 stars$53.34-0.4%$62.20+16.6%-22.4%$1.65B$1.32B12.584,100CDRECadre3.358 of 5 stars$34.51+0.3%$37.50+8.7%+4.3%$1.40B$559.81M41.582,240Insider TradeTNDMTandem Diabetes Care4.2255 of 5 stars$20.04-3.5%$33.43+66.8%-49.5%$1.33B$982.95M-10.382,600Positive NewsAORTArtivion2.5455 of 5 stars$28.68+1.5%$31.40+9.5%+34.5%$1.22B$390.08M-1,433.951,300LQDALiquidia3.885 of 5 stars$14.09-0.1%$26.89+90.8%+9.4%$1.20B$14.14M-8.6450 Related Companies and Tools Related Companies Warby Parker Alternatives NovoCure Alternatives LeMaitre Vascular Alternatives Enovis Alternatives National Vision Alternatives CONMED Alternatives Cadre Alternatives Tandem Diabetes Care Alternatives Artivion Alternatives Liquidia Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXST Stock Free RXST Stock Alerts